Prognostic significance of programmed cell death-ligand 1 expression on immune cells and epithelial-mesenchymal transition expression in patients with hepatocellular carcinoma

被引:0
|
作者
Jung, Hae Il [1 ]
Ahn, Hyein [2 ]
Oh, Mee-Hye [2 ]
Yun, JongHyuk [1 ]
Lee, Hyunyong [1 ]
Bae, Sang Ho [1 ]
Kim, Yung Kil [1 ]
Kim, Sung Yong [1 ]
Baek, Moo-Jun [1 ]
Lee, Moon-Soo [1 ]
机构
[1] Soonchunhyang Univ, Cheonan Hosp, Coll Med, Dept Surg, 31 Suncheonhyang 6 gil, Cheonan 31151, South Korea
[2] Soonchunhyang Univ, Cheonan Hosp, Coll Med, Dept Pathol, Cheonan, South Korea
基金
新加坡国家研究基金会;
关键词
Epithelial-mesenchymal transition; Hepatocellular carcinoma; Prognosis; Programmed cell death 1 ligand 2 protein; Tumor-infiltrating lymphocytes; PD-L1; EXPRESSION; POOR SURVIVAL; INFILTRATION;
D O I
10.4174/astr.2023.105.5.297
中图分类号
R61 [外科手术学];
学科分类号
摘要
Purpose: Immune checkpoint inhibitors (ICIs) have been shown significant oncological improvements in several cancers. However, ICIs are still in their infancy in hepatocellular carcinoma (HCC). Programmed cell death-ligand 1 (PD-L1), tumorinfiltrating cytes (TILs), and epithelial-mesenchymal transition (EMT) have been known as prognostic factors in HCC. Therefore, we have focused on identifying the molecular mechanisms between each marker to evaluate a predictive role. Methods: Formalin-fixed paraffin-embedded samples were obtained from 166 patients with HCC who underwent surgery. The expression of PD-L1 and TILs and EMT marker were evaluated by immunohistochemical analysis. Results: The multivariate analysis showed that TIL expression (hazard ratio [HR], 0.483; 95% confidence interval [CI], 0.269-0.866; P = 0.015) were independent prognostic factors for overall survival. The prognostic factors for disease-free survival were EMT marker expression (HR, 1.565; 95% CI, 1.019-2.403; P = 0.005). Patients with high expression of TILs had significantly better survival compared to patients with low expression (P = 0.023). Patients who were TIL+/EMT- showed a significantly better prognosis than those who were TIL-/EMT+ (P = 0.049). Conclusion: This study demonstrates that PD-L1 expression of TILs is closely associated with EMT marker expression in HCC. Clinical
引用
收藏
页码:297 / 309
页数:13
相关论文
共 50 条
  • [31] The Expression of Programmed Death-Ligand 1 on Immune Cells Is Related to a Better Prognosis in Biliary Tract Cancer
    Kwon, Sung Chan
    Bang, Seungmin
    Park, Young Nyun
    Park, Ji Hoon
    Kim, So Jeong
    Jo, Jung Hyun
    Chung, Moon Jae
    Park, Jeong Youp
    Park, Seung Woo
    Song, Si Young
    Park, Eunhyang
    Lee, Hee Seung
    GUT AND LIVER, 2023, 17 (06) : 933 - 941
  • [32] Programmed Death-ligand 1 Expression in Upper Tract Urothelial Carcinoma
    Skala, Stephanie L.
    Liu, Tzu-Ying
    Udager, Aaron M.
    Weizer, Alon Z.
    Montgomery, Jeffrey S.
    Palapattu, Ganesh S.
    Siddiqui, Javed
    Cao, Xuhong
    Fields, Kristina
    Abugharib, Ahmed E.
    Soliman, Moaaz
    Hafez, Khaled S.
    Miller, David
    Lee, Cheryl T.
    Alva, Ajjai
    Chinnaiyan, Arul M.
    Morgan, Todd M.
    Spratt, Daniel E.
    Jiang, Hui
    Mehra, Rohit
    EUROPEAN UROLOGY FOCUS, 2017, 3 (4-5): : 502 - 509
  • [33] Autophagy controls programmed death-ligand 1 expression on cancer cells (Review)
    Gao, Lijuan
    Chen, Yongshun
    BIOMEDICAL REPORTS, 2021, 15 (04)
  • [34] Increased programmed death ligand-1 expression predicts poor prognosis in hepatocellular carcinoma patients
    Gu, Xiaobin
    Gao, Xian-Shu
    Xiong, Wei
    Guo, Wei
    Han, Linjun
    Bai, Yun
    Peng, Chuan
    Cui, Ming
    Xie, Mu
    ONCOTARGETS AND THERAPY, 2016, 9 : 4805 - 4813
  • [35] Clinical Significance of Combined Epithelial-Mesenchymal Transition Markers Expression and Role of Rac1 in Hepatocellular Carcinoma
    Shin, Seung Kak
    Ryu, Sujin
    Nam, Seungyoon
    Ha, Seung Yeon
    Kwon, Oh Sang
    Kim, Yun Soo
    Kim, Se-Hee
    Kim, Ju Hyun
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (02)
  • [36] Significance of Programmed Cell Death-Ligand 1 Expression and its Association with Survival in Patients with Small Cell Lung Cancer
    Ishii, Hidenobu
    Azuma, Koichi
    Kawahara, Akihiko
    Yamada, Kazuhiko
    Imamura, Yohei
    Tokito, Takaaki
    Kinoshita, Takashi
    Kage, Masayoshi
    Hoshino, Tomoaki
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (03) : 426 - 430
  • [37] Expression of Programmed Death-Ligand 1 in Laryngeal Carcinoma and its Effects on Immune Cell Subgroup Infiltration
    Yu, Dan
    Cheng, Jinzhang
    Xue, Kai
    Zhao, Xue
    Wen, Lianji
    Xu, Chengbi
    PATHOLOGY & ONCOLOGY RESEARCH, 2019, 25 (04) : 1437 - 1443
  • [38] Clinicopathological and Prognostic Significance of Programmed Death Ligand 1 Expression in Korean Patients With Triple-negative Breast Carcinoma
    Kim, Hyun-Soo
    Do, Sung-Im
    Kim, Dong-Hoon
    Apple, Sophia
    ANTICANCER RESEARCH, 2020, 40 (03) : 1487 - 1494
  • [39] Prognostic Impact of Tumor Cell Programmed Death Ligand 1 Expression and Immune Cell Infiltration in NSCLC
    Edlund, Karolina
    Madjar, Katrin
    Mattsson, Johanna S. M.
    Djureinovic, Dijana
    Lindskog, Cecilia
    Brunnstrom, Hans
    Koyi, Hirsh
    Branden, Eva
    Jirstrom, Karin
    Ponten, Fredrik
    Rahnenfuehrer, Joerg
    Micke, Patrick
    Hengstler, Jan G.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (04) : 628 - 640
  • [40] Expression of programmed death ligand-1 and programmed death 1 in hepatocellular carcinoma and its clinical significance
    Long, J.
    Qu, Tao
    Pan, X. F.
    Tang, X.
    Wan, H. H.
    Qiu, P.
    Xu, Yan-Hua
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2018, 14 : S1188 - S1192